Bavarian Nordic and Serum Institute of India Partner to Expand Access to Mpox Vaccine
Bavarian Nordic Partners with Serum Institute of India to Expand Access to Mpox Vaccine
New Agreement Aims to Ensure Global Equity in Vaccine Distribution
In a move to bolster global access to the mpox vaccine, Bavarian Nordic, a leading vaccine developer, has inked a landmark agreement with Serum Institute of India (SII), the world’s largest vaccine manufacturer. This partnership will see SII gain the license to produce and distribute Bavarian Nordic’s MVA-BN vaccine in india, with the potential to expand manufacturing for global distribution.
“Our mission has always been to provide affordable, high-quality vaccines,” said Adar Poonawalla, CEO of SII. “This partnership with Bavarian Nordic strengthens our commitment to protecting vulnerable populations and enhancing pandemic preparedness.”
The agreement, structured on a profit-sharing model, eliminates upfront payments or milestone fees. SII will be responsible for securing regulatory approvals in India,while both companies will share the costs associated with technology transfer.
Paul Chaplin, President and CEO of Bavarian Nordic, emphasized the importance of this collaboration in ensuring equitable access to the MVA-BN vaccine worldwide.”While there are currently no capacity constraints, partnering with SII allows us to guarantee sufficient supply for all countries, notably in the event of future outbreaks,” he stated.
This partnership marks a important step towards addressing the global need for mpox vaccines. Bavarian Nordic is also exploring additional collaborations, particularly with local manufacturers in Africa, to further expand vaccine availability in regions with limited access.
The agreement underscores the commitment of both companies to deliver swift and effective solutions against mpox, safeguarding vulnerable communities and mitigating the global burden of the disease.
Expanding Access to Mpox Vaccine: A Q&A with Dr. [Expert name], Infectious Disease Specialist
NewsDirectory3: The recent agreement between Bavarian Nordic and serum Institute of India to expand the production and distribution of the MVA-BN mpox vaccine is generating notable buzz.Dr. [Expert Name], could you shed some light on the importance of this partnership?
Dr. [Expert Name]: This collaboration is a crucial step towards ensuring equitable global access to the mpox vaccine. by leveraging Serum Institute of India’s vast manufacturing capacity, we can substantially increase the availability of this life-saving vaccine, especially in low- and middle-income countries.
NewsDirectory3: Can you elaborate on the “equitable access” aspect?
Dr.[Expert Name]: The mpox outbreak highlighted existing disparities in global health security. Many countries struggled to access adequate vaccine supplies during the initial phases. This partnership aims to correct that imbalance by establishing sustainable manufacturing capabilities in India and potentially expanding to other regions.
NewsDirectory3: What are the implications of a profit-sharing model in this agreement?
Dr. [Expert Name]: The profit-sharing structure is a commendable aspect of this partnership. It demonstrates a commitment to making the vaccine affordable and accessible to all, nonetheless of their economic status. It also encourages long-term sustainability by ensuring both companies benefit from the collaboration.
NewsDirectory3: What are your thoughts on the potential expansion to Africa?
Dr. [Expert Name]: Expanding vaccine production in Africa is vital. It strengthens local health systems, fosters self-reliance, and ensures timely access to vaccines during outbreaks. This is a promising growth that could have a transformative impact on the continent’s preparedness for future health emergencies.
NewsDirectory3: Looking ahead, what does this partnership signify for the future of pandemic preparedness?
Dr. [Expert name]: It sets a powerful precedent for international collaboration in vaccine development and distribution. By prioritizing equity and accessibility, this partnership serves as a model for future responses to emerging infectious diseases. This collaborative approach is essential for safeguarding global health security.